BioSpace News Archive

Business

Myrobalan Claims $24M for Portfolio of Neurorestorative Drugs

The Massachusetts–based startup will use the Series A funds to advance its pipeline of oral GPR17, CSF1R and TYK2 candidates.

January 10, 2024
·
2 min read
·
Tristan Manalac
Business

FDA’s CAR T Probe ‘Not a Big Deal’ for Oncology-Focused Biotechs: Triumvira President

Triumvira Immunologics’ president and chief operating officer Rob Williamson noted that cell therapy companies might still have an uphill battle unless they can differentiate.

January 10, 2024
·
2 min read
·
Tyler Patchen
Drug Development

Alcon’s Investigational Drops Show Promising Phase III Data in Dry Eye Disease

Patients treated with AR-15512 showed higher rates of at least a 10-mm improvement in unanesthetized Schirmer’s score, a metric of tear production.

January 10, 2024
·
2 min read
·
Tristan Manalac
JPM2024: Big Tech Poised to Disrupt Biopharma with AI-Based Drug Discovery

On Sunday, ahead of the J.P. Morgan Healthcare Conference, Alphabet’s artificial intelligence startup Isomorphic Labs secured its first pharma partnerships with Eli Lilly and Novartis worth nearly $3 billion.

January 10, 2024
·
3 min read
·
Greg Slabodkin
13 Therapies Make Clarivate’s 2024 Drugs to Watch List

Clarivate’s latest Drug to Watch list highlights new modalities shaping drug development, including gene editing and artificial intelligence.

January 10, 2024
·
4 min read
·
Patience Asanga
BCG Panel: ‘No Single Approach’ to Maximizing Generative AI in Biotech and Healthcare

For experts on Boston Consulting Group’s generative AI panel, effectively using the technology in the biotech industry will be a collaborative process.

January 10, 2024
·
2 min read
·
Tyler Patchen
Gilead Sciences Must Face Consumer Claims Over Older, Lower-Quality Drugs, Court Rules

Gilead’s stock traded lower on news that claims will proceed that allege the company delayed the development of newer, safer HIV drugs in order to maximize profits.

January 10, 2024
·
2 min read
·
Connor Lynch
Deals

Listen: JPM2024 Day 3 Highlights

The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 3 at JPM2024.

January 10, 2024
·
1 min read
·
Lori Ellis
Drug Development

Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01

Spago Nanomedical AB announced that the independent data monitoring committee has recommended a dose escalation in the company’s clinical phase I/IIa study Tumorad-01 with the candidate drug 177Lu-SN201.

January 10, 2024
·
1 min read
More accurate tumour treatment thanks to superconductive ASG Superconductors technology

ASG Superconductors’ MgB2 superconducting technology is at the heart of the worldwide innovation presented in Dresden in the field of proton therapy and cancer treatment using real-time MRI imaging.

January 10, 2024
·
3 min read